ACADIA Pharmaceuticals Inc. Forecast, price target & analysts
ACADIA Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation
ACADIA Pharmaceuticals Inc. Classifications & Recommendation:
ACADIA Pharmaceuticals Inc. Price Target
| Target Price | $24.85 |
| Price | $16.12 |
| Potential |
54.16%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target ACADIA Pharmaceuticals Inc. 2026 .
The average ACADIA Pharmaceuticals Inc. target price is $24.85.
This is
54.16%
register free of charge
$37.00
129.53%
register free of charge
$11.00
31.76%
register free of charge
|
|
| A rating was issued by 20 analysts: 12 Analysts recommend ACADIA Pharmaceuticals Inc. to buy, 7 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ACADIA Pharmaceuticals Inc. stock has an average upside potential 2026 of
54.16%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 957.80 | 1,061.90 |
| 31.85% | 10.87% | |
| EBITDA Margin | 10.46% | 9.17% |
| 211.99% | 12.31% | |
| Net Margin | 23.67% | 8.52% |
| 378.78% | 64.01% |
20 Analysts have issued a sales forecast ACADIA Pharmaceuticals Inc. 2025 . The average ACADIA Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an ACADIA Pharmaceuticals Inc. EBITDA forecast 2025. The average ACADIA Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
20 ACADIA Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average ACADIA Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.36 | 0.54 |
| 467.57% | 60.29% | |
| P/E | 29.71 | |
| EV/Sales | 1.87 |
20 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast for earnings per share. The average ACADIA Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
ACADIA Pharmaceuticals Inc....
Current ACADIA Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jan 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 07 2024 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Feb 11 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jan 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 07 2024 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
